### SUPPLEMENTARY MATERIAL

# Molecular docking reveals the potential of *Cleome amblyocarpa* isolated compounds to inhibit COVID-19 virus main protease

Ahmed A. Zaki<sup>a</sup>, Ahmed A. Al-Karmalawy<sup>b</sup>, Yasser A. El-Amier<sup>d</sup>, Ahmed Ashour<sup>a,c</sup>

<sup>a</sup>Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. <sup>b</sup>Department of Medicinal Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt.

<sup>c</sup>Department of Pharmacognosy, Faculty of Pharmacy, Horus University, New Damietta, Egypt.

<sup>d</sup>Botany Department, Ecology, Faculty of Science, Mansoura University, Mansoura 35516, Egypt.

#### Abstract

Nine flavonoids and one saponin were isolated from the aerial parts of *Cleome amblyocarpa*. Molecular Docking of isolated compounds on COVID-19 virus main protease showed variable binding affinities with scores ranging from (-8.63 to -6.08) compared to N3 inhibitor (-10.10) and binding modes better than N3 inhibitor in some of the isolated compounds. The descending order of binding affinity of the tested drugs was as follow; N3 inhibitor (**11**, docked) > kaempferitrin (**6**) > isorhamnetin 3,7-*O*- $\alpha$ -L-dirhamnoside (**3**) > kaempferol 3-*O*- $\beta$ glucoside-7-*O*- $\alpha$ -rhamnoside (**2**) > soysaponin (**1**) > isorhamnetin 7-*O*- $\alpha$ -L-rhamnoside (**10**) > genistein-8-C-glucoside (**8**) > tamarixetin 7-*O*- $\beta$ -D-glucoside (**4**) > isoprunetin-7-glucoside (**9**) > genistin (**5**) > 5-*O*-methylgenistein (**7**). These results could be a good start for fast further examining the isolated compounds *in vitro* and *in vivo* either alone or in combinations for the treatment of COVID-19 virus. In addition, this work gives an explanation on the SAR required for targeting the newly emerged SARS-CoV-2 protease and facilitates the future design and synthesis of new drugs targeting it as well.

Key words: COVID-19; Cleome amblyocarpa; molecular docking; flavanoids

\*Corresponding authors:

#### **Ahmed Ashour**

Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. Email: <a href="mailto:ahmedadelashour@yahoo.com">ahmedadelashour@yahoo.com</a>

## List of figures

No.	Title
<b>S</b> 1	<sup>1</sup> H - NMR spectrum (DMSO- $d_6$ , 400 MHz) of compound <b>1</b>
S2	<sup>13</sup> C NMR spectrum (DMSO- $d_6$ , 100 MHz) of compound <b>1</b>
<b>S3</b>	<sup>1</sup> H - NMR spectrum (DMSO- $d_6$ , 400 MHz) of compound <b>2</b>
<b>S4</b>	<sup>13</sup> C NMR spectrum (DMSO- $d_6$ , 100 MHz) of compound <b>2</b>
<b>S</b> 5	<sup>1</sup> H - NMR spectrum (DMSO- $d_6$ , 400 MHz) of compound <b>3</b>
<b>S6</b>	<sup>13</sup> C NMR spectrum (DMSO- $d_6$ , 100 MHz) of compound <b>3</b>
<b>S7</b>	<sup>1</sup> H - NMR spectrum (DMSO- $d_6$ , 400 MHz) of compound 4
<b>S8</b>	<sup>13</sup> C NMR spectrum (DMSO- $d_6$ , 100 MHz) of compound <b>4</b>
<b>S9</b>	<sup>1</sup> H - NMR spectrum (DMSO- $d_6$ , 400 MHz) of compound <b>5</b>
<b>S10</b>	<sup>13</sup> C NMR spectrum (DMSO- $d_6$ , 100 MHz) of compound <b>5</b>
<b>S11</b>	<sup>1</sup> H - NMR spectrum (DMSO- $d_6$ , 400 MHz) of compound <b>6</b>
<b>S12</b>	<sup>13</sup> C NMR spectrum (DMSO- $d_6$ , 100 MHz) of compound <b>6</b>
<b>S13</b>	<sup>1</sup> H - NMR spectrum (DMSO- $d_6$ , 400 MHz) of compound 7
<b>S14</b>	<sup>13</sup> C NMR spectrum (DMSO- $d_6$ , 100 MHz) of compound 7
S15	<sup>1</sup> H - NMR spectrum (CD <sub>3</sub> OD, 400 MHz) of compound <b>8</b>
<b>S16</b>	<sup>13</sup> C NMR spectrum (CD <sub>3</sub> OD, 100 MHz) of compound <b>8</b>
<b>S17</b>	<sup>1</sup> H - NMR spectrum (CD <sub>3</sub> OD, 400 MHz) of compound <b>9</b>
<b>S18</b>	<sup>13</sup> C NMR spectrum (CD <sub>3</sub> OD, 100 MHz) of compound <b>9</b>
<b>S19</b>	<sup>1</sup> H - NMR spectrum (DMSO- $d_6$ , 400 MHz) of compound <b>10</b>
S20	<sup>13</sup> C NMR spectrum (DMSO- $d_6$ , 100 MHz) of compound <b>10</b>



Figure S1: <sup>1</sup>H - NMR spectrum (DMSO-*d*<sub>6</sub>, 400 MHz) of compound 1



Figure S2: <sup>13</sup>C NMR spectrum (DMSO-*d*<sub>6</sub>, 100 MHz) of compound 1



Figure S3: <sup>1</sup>H - NMR spectrum (DMSO-*d*<sub>6</sub>, 400 MHz) of compound 2



Figure S4: <sup>13</sup>C NMR spectrum (DMSO-*d*<sub>6</sub>, 100 MHz) of compound 2



Figure S5: <sup>1</sup>H - NMR spectrum (DMSO-*d*<sub>6</sub>, 400 MHz) of compound **3** 



Figure S6: <sup>13</sup>C NMR spectrum (DMSO-*d*<sub>6</sub>, 100 MHz) of compound **3** 



Figure S8: <sup>13</sup>C NMR spectrum (DMSO-*d*<sub>6</sub>, 100 MHz) of compound 4



Figure S9: <sup>1</sup>H - NMR spectrum (DMSO-*d*<sub>6</sub>, 400 MHz) of compound 5



Figure S10: <sup>13</sup>C NMR spectrum (DMSO-*d*<sub>6</sub>, 100 MHz) of compound 5



Figure S11: <sup>1</sup>H - NMR spectrum (DMSO-*d*<sub>6</sub>, 400 MHz) of compound 6



Figure S12: <sup>13</sup>C NMR spectrum (DMSO-*d*<sub>6</sub>, 100 MHz) of compound 6



Figure S13: <sup>1</sup>H - NMR spectrum (DMSO-*d*<sub>6</sub>, 400 MHz) of compound 7



Figure S14: <sup>13</sup>C NMR spectrum (DMSO-*d*<sub>6</sub>, 100 MHz) of compound 7



Figure S15: <sup>1</sup>H - NMR spectrum (CD<sub>3</sub>OD, 400 MHz) of compound 8



Figure S16: <sup>13</sup>C NMR spectrum (CD<sub>3</sub>OD, 100 MHz) of compound 8



Figure S17: <sup>1</sup>H - NMR spectrum (CD<sub>3</sub>OD, 400 MHz) of compound 9



Figure S18: <sup>13</sup>C NMR spectrum (CD<sub>3</sub>OD, 100 MHz) of compound 9



Figure S19: <sup>1</sup>H - NMR spectrum (DMSO-*d*<sub>6</sub>, 400 MHz) of compound 10



Figure S20: <sup>13</sup>C NMR spectrum (DMSO-*d*<sub>6</sub>, 400 MHz) of compound 10